Michael J. Dolton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael J. Dolton has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
A. Quartino
Genentech, Inc., South San Francisco, USA
1 shared publicationAaron Chesterman
Genentech, Inc. South San Francisco California USA
1 shared publication- Ajay Deshmukh
Genentech, Inc. South San Francisco California USA
1 shared publication Amanda Roden
Genentech, Inc. South San Francisco California USA
1 shared publicationAngelica Quartino
Genentech, Inc. South San Francisco California USA
1 shared publicationAnita Moein
Genentech, Inc. South San Francisco California USA
1 shared publication
Latest Publications
- Open Access
- 19 January 2023
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 10 (2) , 212-222
Longitudinal Exposure—Response Modeling of Multiple Indicators of Alzheimer's Disease Progression
Progression in Alzheimer’s disease manifests as changes in multiple biomarker, cognitive, and functional endpoints. Disease progression modeling can
- 19 January 2023
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 10 (2) , 212-222
Open AccessLongitudinal Exposure—Response Modeling of Multiple Indicators of Alzheimer's Disease Progression
Progression in Alzheimer’s disease manifests as changes in multiple biomarker, cognitive, and functional endpoints. Disease progression modeling can
- 4 August 2021
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (5) , 1337-1348
Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers
Compared with intravenous formulations, subcutaneous (s.c.) formulations of therapeutic monoclonal antibodies may provide increased patient access and more convenient administration options, although historically high‐volume s.c. administration (> 10–15 mL) has been challenging. We report results from two phase I studies in healthy participants (GP29523 and GP40201) that evaluated s.c. crenezumab, an anti‐Aβ monoclonal antibody in development for individuals at risk for autosomal‐dominant Alzheimer’s disease. GP29523 assessed safety, tolerability, and pharmacokinetics (PK) in 68 participants (aged 50–80 years) who received single ascending doses (600–7,200 mg) of crenezumab or placebo (4–40 mL). GP40201 assessed safety, tolerability, and PK in 72 participants (aged 18–80 years) who received different combinations of dose (1,700–6,800 mg), infusion volume (10–40 mL), and flow rate (2–4 mL/minute), with/without recombinant human hyaluronidase (rHuPH20). There were no serious or dose‐limiting adverse events in either study. There were no meaningful differences in pain scores among reference placebo (4 mL), test placebo (4–40 mL), or crenezumab (600–7,200 mg) in GP29523, or across treatments with varying infusion volume, flow rate, dose, or rHuPH20 co‐administration or concentration in GP40201. Transient erythema was the most common infusion site reaction in both studies. In GP40201 at volumes of ≥ 20 mL, rHuPH20 co‐administration appeared to reduce infusion site swelling incidence, but, in some cases, was associated with larger areas of infusion site erythema. Crenezumab exhibited approximately dose‐proportional PK, and s.c. bioavailability was 66% and independent of dose or rHuPH20 co‐administration. High‐dose, high‐concentration, high‐volume s.c. crenezumab formulated with/without rHuPH20 was well‐tolerated in healthy participants, with an acceptable safety profile.
- 4 August 2021
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (5) , 1337-1348
Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers
Compared with intravenous formulations, subcutaneous (s.c.) formulations of therapeutic monoclonal antibodies may provide increased patient access and more convenient administration options, although historically high‐volume s.c. administration (> 10–15 mL) has been challenging. We report results from two phase I studies in healthy participants (GP29523 and GP40201) that evaluated s.c. crenezumab, an anti‐Aβ monoclonal antibody in development for individuals at risk for autosomal‐dominant Alzheimer’s disease. GP29523 assessed safety, tolerability, and pharmacokinetics (PK) in 68 participants (aged 50–80 years) who received single ascending doses (600–7,200 mg) of crenezumab or placebo (4–40 mL). GP40201 assessed safety, tolerability, and PK in 72 participants (aged 18–80 years) who received different combinations of dose (1,700–6,800 mg), infusion volume (10–40 mL), and flow rate (2–4 mL/minute), with/without recombinant human hyaluronidase (rHuPH20). There were no serious or dose‐limiting adverse events in either study. There were no meaningful differences in pain scores among reference placebo (4 mL), test placebo (4–40 mL), or crenezumab (600–7,200 mg) in GP29523, or across treatments with varying infusion volume, flow rate, dose, or rHuPH20 co‐administration or concentration in GP40201. Transient erythema was the most common infusion site reaction in both studies. In GP40201 at volumes of ≥ 20 mL, rHuPH20 co‐administration appeared to reduce infusion site swelling incidence, but, in some cases, was associated with larger areas of infusion site erythema. Crenezumab exhibited approximately dose‐proportional PK, and s.c. bioavailability was 66% and independent of dose or rHuPH20 co‐administration. High‐dose, high‐concentration, high‐volume s.c. crenezumab formulated with/without rHuPH20 was well‐tolerated in healthy participants, with an acceptable safety profile.